Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

2.

Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.

Nairooz R, Sardar P, Amin H, Swaminathan RV, Kim LK, Chatterjee S, Feldman DN.

Am J Cardiol. 2014 Jul 15;114(2):250-9. doi: 10.1016/j.amjcard.2014.04.033. Epub 2014 May 2. Review.

PMID:
24890986
3.

Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis.

De Luca G, Gibson CM, Bellandi F, Murphy S, Maioli M, Noc M, Zeymer U, Dudek D, Arntz HR, Zorman S, Gabriel HM, Emre A, Cutlip D, Biondi-Zoccai G, Rakowski T, Gyongyosi M, Marino P, Huber K, van't Hof AW.

Heart. 2008 Dec;94(12):1548-58. doi: 10.1136/hrt.2008.141648. Epub 2008 May 12. Review.

4.

Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future.

De Luca G, Savonitto S, van't Hof AW, Suryapranata H.

Drugs. 2015 Jul;75(11):1229-53. doi: 10.1007/s40265-015-0425-7. Review.

PMID:
26177890
5.
6.

Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials.

Tricoci P, Newby LK, Hasselblad V, Kong DF, Giugliano RP, White HD, Théroux P, Stone GW, Moliterno DJ, Van de Werf F, Armstrong PW, Prabhakaran D, Rasoul S, Bolognese L, Durand E, Braunwald E, Califf RM, Harrington RA.

Circ Cardiovasc Qual Outcomes. 2011 Jul;4(4):448-58. doi: 10.1161/CIRCOUTCOMES.110.960294. Epub 2011 Jun 28. Review.

7.

The use of glycoprotein IIb/IIIa inhibitor therapy in acute ST-segment elevation myocardial infarction: current practice and future trends.

Campbell KR, Ohman EM, Cantor W, Lincoff AM.

Am J Cardiol. 2000 Apr 27;85(8A):32C-8C. Review.

PMID:
10793178
8.

Meta-analysis of randomized controlled trials comparing intracoronary and intravenous administration of glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction.

Wang Y, Wu B, Shu X.

Am J Cardiol. 2012 Apr 15;109(8):1124-30. doi: 10.1016/j.amjcard.2011.11.053. Epub 2012 Jan 14. Review.

PMID:
22245413
10.

[The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].

Galli M, Maggioni AP, Vassanelli C, Tavazzi L.

Ital Heart J Suppl. 2000 Feb;1(2):202-11. Review. Italian.

PMID:
10731377
12.

Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.

Bosch X, Marrugat J, Sanchis J.

Cochrane Database Syst Rev. 2013 Nov 8;(11):CD002130. doi: 10.1002/14651858.CD002130.pub4. Review.

PMID:
24203004
13.
15.

Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.

Bosch X, Marrugat J, Sanchis J.

Cochrane Database Syst Rev. 2013 Oct 18;(10):CD002130. doi: 10.1002/14651858.CD002130.pub3. Review. Update in: Cochrane Database Syst Rev. 2013;(11):CD002130.

PMID:
24136036
16.

The role of eptifibatide in patients undergoing percutaneous coronary intervention.

Zeymer U.

Expert Opin Pharmacother. 2007 Jun;8(8):1147-54. Review.

PMID:
17516878
17.

Appropriate bolus administration of glycoprotein IIb/IIIa inhibitors for patients with acute coronary syndromes undergoing percutaneous coronary intervention: intracoronary or intravenous? A comprehensive and updated meta-analysis and systematic review.

Ali-Hasan-Al-Saegh S, Mirhosseini SJ, Shahidzadeh A, Rahimizadeh E, Sarrafan-Chaharsoughi Z, Ghodratipour Z, Lotfaliani M, Rezaeisadrabadi M, Dehghan HR, Bireta C, Weymann A, Sabashnikov A, Popov AF.

Kardiol Pol. 2016;74(2):104-18. doi: 10.5603/KP.a2015.0138. Epub 2015 Jul 23. Review.

18.

Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.

Bhatt DL, Topol EJ.

JAMA. 2000 Sep 27;284(12):1549-58. Review.

PMID:
11000650
19.

Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban.

van 't Hof AW, Valgimigli M.

Drugs. 2009;69(1):85-100. doi: 10.2165/00003495-200969010-00006. Review.

PMID:
19192938
20.

Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease.

Vorchheimer DA, Badimon JJ, Fuster V.

JAMA. 1999 Apr 21;281(15):1407-14. Review.

PMID:
10217057

Supplemental Content

Support Center